Randomized phase II study of clinical effect of ghrelin administration for DCF with esophageal cancer patients
Phase 2
- Conditions
- patients with esophageal cancer, undergoing chemotherapy
- Registration Number
- JPRN-UMIN000018162
- Lead Sponsor
- Osaka University School of Medicine Gastroenterological Surgery
- Brief Summary
Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with severe co morbid conditions 2. other active malignancy 3. judged as inappropriate by physician-in-charge 4. combination with radiation therapy 5. lactation and pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method